Intravitreal injections: Is there benefit for a theatre setting?

British Journal of Ophthalmology

Volumn 96, Issue 12, 2012, Pages 1474-1478

  Abell, Robin G ^a   Kerr, Nathan M ^b   Allen, Penelope ^a   Vote, Brendan J ^a,b  

^a Tasmanian Eye Institute   (Australia)

^b Launceston Eye Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; RANIBIZUMAB; VANCOMYCIN;

AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; CASE REPORT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; ENDOPHTHALMITIS; FEMALE; HAEMOPHILUS; HEALTH CARE FACILITY; HUMAN; INCIDENCE; INFECTION RISK; MALE; OPERATING ROOM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOPHTHALMITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TASMANIA;

EID: 84869867264     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302030     Document Type: Article

References (46)

1. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-82.
2. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118:2028-34.
3. Moshfeghi AA, Rosenfeld PJ, Flynn HW, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-8.
4. Li J, Morlet N, Ng JQ, et al. Significant nonsurgical risk factors for endophthalmitis after cataract surgery: EPSWA fourth report. Invest Ophthalmol Vis Sci 2004;45:1321-8.
5. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-9.
6. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-7.
7. Moshfeghi AA. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Semin Ophthalmol 2011;26:139-48.
8. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98.
9. Inoue M, Kobayakawa S, Sotozono C, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 2011;226:145-50.
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
11. Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
12. Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
13. The Royal College of Ophthalmologists, United Kingdom. The UK Guidelines for Intravitreal Injections Procedure 2009. http://www.rcophth.ac.uk/core/core- picker/ download.asp?id=167&filetitle= Guidelines+for+Intravitreal+Injections+Procedure+2009 (accessed 4 May 2012).
14. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2005;25:949-50.
15. Frenkel RE, Haji SA, La M, et al. A protocol for the retina surgeon's safe initial intravitreal injections. Clin Ophthalmol 2010;4:1279-85.
16. Simunovic MP, Rush RB, Hunyor AP, et al. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. Published Online First: 24 March 2012. doi:10.1136/bjophthalmol- 2011-301439
17. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2006. Catalogue no: 2033.0.55.001. http://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001/ (accessed 20 Aug 2012).
18. Australian Day Surgery Council, Royal Australasian College of Surgeons, Australian New Zealand College of Anaesthetists and the Australian Society of Anaesthetists. Report and Recommendations on Office-Based Surgery Development in Australia. Guidelines for Office-Based Surgery. Revised 2004. http://www.health.gov.au/internet/main/publishing.nsf/Content/ health-privatehealth-providers-circulars00-01-710-446.htm/$FILE/710-446a. pdf (accessed 4 May 2012).
19. Bhavsar AR, Googe JM Jr, Stockdale CR, et al. The risk of endophthalmitis following intravitreal injection in the DRCR.net laser-ranibizumab- triamcinolone clinical trials. Arch Ophthalmol 2009;127:1581-3.
20. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116:720-1.
21. Singer MA, Awh CC, Sadda SV. Horizon: an open-label extension trial of ranibizumab for choroidal neovascularisation secondary to age-related macular degeneration. Ophthalmology. Published Online First: 4 February 2012. doi:10.1016/j.ophtha.2011.12.016
22. Mino de Kaspar H, Chang RT, Singh K, et al. Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery. Arch Ophthalmol 2005;123:161-5.
23. Nentwich MM, Rajab M, Ta CN, et al. Application of 10% povidone iodine reduces conjunctival bacterial contamination rate in patients undergoing cataract surgery. Eur J Ophthalmol. Published Online First: 6 December 2011. doi:10.5301/ejo.5000093
24. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol 2007;27:307-12.
25. De Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008;28:877-83.
26. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12.
27. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29:601-5.
28. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina 2012;32:473-6.
29. Tanner J, Swarbrook S, Stuart J. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev 2008;(1):CD004288.
30. Wen JC, McCannel CA, Mochon AB, et al. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551-4.
31. Philips BJ, Fergusson S, Armstrong P, et al. Surgical face masks are effective in reducing bacterial contamination caused by dispersal from the upper airway. Br J Anaesth 1992;69:407-8.
32. Chen E, Lin MY, Cox J, et al. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011;31:1525-33.
33. Chow TT, Yang XY. Ventilation performance in operating theatres against airborne infection: review of research activities and practical guidance. J Hosp Infect 2004;56:85-92.
34. Hirsch T, Hubert H, Fischer S, et al. Bacterial burden in the operation room: impact of airflow systems. Am J Infect Control. Published Online First: 25 April 2012. doi:10.1016/j.ajic.2012.01.007
35. Ta CN. Minimizing the risk of endophthalmitis following intravitreal injections. Retina 2004;24:699-705.
36. Rooney AL, van Ostenberg P. R Licensure, accreditation, and certification: approaches to health services quality. Bethesda. USA: Quality Assurance Project, 1999. http://www.hciproject.org/sites/default/files/ Licensure,%20accreditation,% 20and%20certification%20Approaches%20to%20health%20services%20quality-0.pdf (accessed 7 May 2012).
37. The Australian Council on Healthcare Standards. EQuIP5 Day Procedure Centres Guide & Expanded Clinical Guidelines. http://www.achs.org.au/ equip5publications (accessed 7 May 2012).
38. NHMRC. Clinical educators guide for the prevention and control of infection in healthcare. Commonwealth of Australia, 2010. http://www.nhmrc.gov. au/-files-nhmrc/publications/attachments/cd33-icg-clinical-ed-guide-web.pdf (accessed 7 May 2012).
39. Murphy EK. Patient safety and risk management. In: Rothrock JC, ed. Alexander's care of the patient in surgery, 14th edn. St Louis, MI: Elsevier Mosby, 2011:18-47.
40. Hancox JG, Venkat AP, Coldiron B, et al. The safety of office-based surgery: review of recent literature from several disciplines. Arch Dermatol 2004; 140:1379-82.
41. Bartholomeusz H. The need for regulation of office-based procedures. Med J Aust 2012;196:492-3.
42. Australian Bureau of Statistics 2006, National Health Survey: Summary of Results, Australia 2004-05, cat no. 4264.0. Canberra: ABS, 2006.
43. Ravindran RD, Venkatesh R, Chang DF, et al. Incidence of post-cataract endophthalmitis at Aravind Eye Hospital: outcomes of more than 42,000 consecutive cases using standardized sterilization and prophylaxis protocols. J Cataract Refract Surg 2009;35:629-36.
44. Das T, Hussain A, Naduvilath T, et al. Case control analyses of acute endophthalmitis after cataract surgery in South India associated with technique, patient care, and socioeconomic status. J Ophthalmology Published Online First 23 February 2012. doi:10.1155/2012/298459.
45. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-61.
46. Shultz RW, Bakri SJ. Treatment for submacular haemorrhage associated with neovascular age-related macular degeneration. Semin Ophthalmol 2011;26:361-71.